CR20190301A - Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer - Google Patents
Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncerInfo
- Publication number
- CR20190301A CR20190301A CR20190301A CR20190301A CR20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- salts
- methods
- dna
- mediated disease
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical class NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 13
- 150000003839 salts Chemical class 0.000 abstract 13
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000543 intermediate Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de Fórmula (I):y sales farmacéuticamente aceptables de los mismos, donde R1 y R2 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436619P | 2016-12-20 | 2016-12-20 | |
| PCT/EP2017/083625 WO2018114999A1 (en) | 2016-12-20 | 2017-12-19 | Amino-triazolopyridine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190301A true CR20190301A (es) | 2019-09-04 |
Family
ID=60937727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190301A CR20190301A (es) | 2016-12-20 | 2017-12-19 | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10407446B2 (es) |
| EP (1) | EP3558997B1 (es) |
| JP (1) | JP6883653B2 (es) |
| KR (1) | KR102220971B1 (es) |
| CN (1) | CN110177791B (es) |
| AR (1) | AR110400A1 (es) |
| AU (1) | AU2017384388B2 (es) |
| BR (1) | BR112019012217B1 (es) |
| CA (1) | CA3046339C (es) |
| CL (1) | CL2019001714A1 (es) |
| CO (1) | CO2019007810A2 (es) |
| CR (1) | CR20190301A (es) |
| CY (1) | CY1124239T1 (es) |
| DK (1) | DK3558997T3 (es) |
| DO (1) | DOP2019000168A (es) |
| EA (1) | EA037745B1 (es) |
| EC (1) | ECSP19044159A (es) |
| ES (1) | ES2867274T3 (es) |
| HR (1) | HRP20210548T1 (es) |
| HU (1) | HUE054548T2 (es) |
| IL (1) | IL267158B (es) |
| JO (1) | JOP20190151B1 (es) |
| LT (1) | LT3558997T (es) |
| MA (1) | MA47079B1 (es) |
| MX (1) | MX390535B (es) |
| MY (1) | MY183036A (es) |
| NI (1) | NI201900062A (es) |
| NZ (1) | NZ755222A (es) |
| PE (1) | PE20191474A1 (es) |
| PH (1) | PH12019501350B1 (es) |
| PL (1) | PL3558997T3 (es) |
| PT (1) | PT3558997T (es) |
| RS (1) | RS61701B1 (es) |
| SI (1) | SI3558997T1 (es) |
| SM (1) | SMT202100225T1 (es) |
| TW (1) | TWI776835B (es) |
| UA (1) | UA123032C2 (es) |
| WO (1) | WO2018114999A1 (es) |
| ZA (1) | ZA201904695B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20191474A1 (es) | 2016-12-20 | 2019-10-16 | Astrazeneca Ab | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020186211A1 (en) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Methods and compositions for treating polyoma virus infection |
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| US20230022146A1 (en) | 2019-06-17 | 2023-01-26 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| CA3159110A1 (en) * | 2019-11-22 | 2021-05-27 | Kevin X Chen | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
| CA3159290A1 (en) * | 2019-11-25 | 2021-06-03 | Kevin X Chen | Pyrimidoimidazole compounds used as dna-pk inhibitors |
| PE20221324A1 (es) * | 2019-11-26 | 2022-09-09 | Primmune Therapeutics Inc | Agonistas del tlr7 |
| EP4086258A4 (en) * | 2019-12-31 | 2023-11-29 | Chengdu Baiyu Pharmaceutical Co., Ltd. | PURINE DERIVATIVE AND ITS MEDICAL USE |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| WO2021136462A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN113493471B (zh) * | 2020-04-03 | 2024-06-11 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
| AU2021256235B2 (en) * | 2020-04-17 | 2024-05-09 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Imidazolidinone derivatives and medical use thereof |
| CN113549092B (zh) * | 2020-04-23 | 2022-10-18 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| KR20230017783A (ko) | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
| AU2021346954A1 (en) * | 2020-09-24 | 2023-05-25 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| CA3205138A1 (en) | 2020-12-17 | 2022-06-23 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| WO2022135555A1 (zh) * | 2020-12-24 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| CN116917288B (zh) * | 2021-03-22 | 2026-04-14 | 成都赜灵生物医药科技股份有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| MX2023012236A (es) | 2021-04-17 | 2024-01-23 | Intellia Therapeutics Inc | Inhibidores de proteína cinasa dependente de acido desoxirribonucleico (and) y composiciones y usos de los mismos. |
| EP4342899A1 (en) * | 2021-05-19 | 2024-03-27 | Zai Lab (Shanghai) Co., Ltd. | Salt form and crystal form of heterocyclic substituted purinone derivative |
| WO2023274310A1 (zh) * | 2021-06-29 | 2023-01-05 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023395B (zh) * | 2021-10-25 | 2025-07-15 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| AU2023389547A1 (en) | 2022-12-06 | 2025-07-17 | Astrazeneca Ab | Polq inhibitors |
| CN121794270A (zh) * | 2023-07-21 | 2026-04-03 | 钟卫 | 取代的2-氨基-9-(3,3-二氟哌啶-4-基)-7,9-二氢-8h-嘌呤-8-酮化合物及其在癌症治疗中的用途 |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025181336A1 (en) | 2024-03-01 | 2025-09-04 | Cellectis Sa | Compositions and methods for hbb-editing in hspc |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| KR20060129023A (ko) | 2004-02-23 | 2006-12-14 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규한 헤테로환 화합물 |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007035873A1 (en) | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| US20080004295A1 (en) | 2005-10-13 | 2008-01-03 | Gore Paul M | Novel compounds |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| CL2007002866A1 (es) * | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| CA2689429C (en) | 2007-06-15 | 2012-08-21 | Banyu Pharmaceutical Co., Ltd. | Bicycloaniline derivatives |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| SG183155A1 (en) | 2010-02-03 | 2012-09-27 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| KR101830455B1 (ko) | 2010-04-13 | 2018-02-20 | 노파르티스 아게 | 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물 |
| BR112013026744B1 (pt) | 2011-04-21 | 2022-05-17 | Origenis Gmbh | Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| CN107137402A (zh) * | 2012-03-15 | 2017-09-08 | 西格诺药品有限公司 | 用tor激酶抑制剂治疗癌症 |
| CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| JP2016516671A (ja) | 2013-02-28 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤を用いたがんの治療 |
| NO2714752T3 (es) | 2014-05-08 | 2018-04-21 | ||
| PE20191474A1 (es) | 2016-12-20 | 2019-10-16 | Astrazeneca Ab | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer |
-
2017
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active Active
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 SM SM20210225T patent/SMT202100225T1/it unknown
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es active IP Right Grant
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/en not_active Ceased
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/en active Active
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 CA CA3046339A patent/CA3046339C/en active Active
- 2017-12-19 MX MX2019007189A patent/MX390535B/es unknown
- 2017-12-19 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 PH PH1/2019/501350A patent/PH12019501350B1/en unknown
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer |